NFE2L2 and early-onset autosomal dominant Alzheimer disease: Meanwhile, administration of 14,15-EET or improving the level of EETs via suppressing sEH reduced cell apoptosis, inflammatory response, and oxidative stress by GSK3β-mediated p53, NF-κB, and Nrf2 signaling pathways in the kidney and central nervous system diseases 51, 59, 61, such as AKI, Parkinson's and Alzheimer's diseases.